Literature DB >> 18441171

Autofluorescence of choroidal melanoma in 51 cases.

C L Shields1, C Bianciotto, C Pirondini, M A Materin, S A Harmon, J A Shields.   

Abstract

AIM: To describe the autofluorescence features of choroidal melanoma.
DESIGN: Non-comparative case series. PARTICIPANTS: 51 consecutive patients.
METHODS: Standard fundus photography and autofluorescence photography (580 nm excitation, 695 nm barrier filter) were performed on all patients. Clinical features were correlated with autofluorescence features. MAIN OUTCOME MEASURE: Autofluorescence features of choroidal melanoma and overlying retinal pigment epithelium (RPE).
RESULTS: The mean patient age was 59 years. The choroidal melanoma was a mean of 3.6 mm from the optic disc and 2.6 mm from the foveola. The mean tumour basal dimension was 11 mm and the mean tumour thickness was 4 mm. The choroidal melanoma showed intrinsic hypoautofluorescence (39%), isoautofluorescence (6%) and hyperautofluorescence (55%). Slightly increased hyperautofluorescence of the melanoma was found in pigmented tumours (versus non-pigmented), those with greater thickness and basal dimensions, and those with overlying disrupted RPE. Related RPE hyperplasia and atrophy showed hypoautofluorescence, drusen, RPE detachment and subretinal fluid showed slight hyperautofluorescence, and orange pigment displayed the brightest hyperautofluorescence.
CONCLUSIONS: Choroidal melanoma generally shows slight intrinsic hyperautofluorescence and the brightness increases with pigmented tumours, larger tumours, and those associated with disrupted RPE. Overlying orange pigment shows remarkably bright hyperautofluorescence.

Entities:  

Mesh:

Year:  2008        PMID: 18441171     DOI: 10.1136/bjo.2007.130286

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  9 in total

1.  Comparison of conventional color fundus photography and multicolor imaging in choroidal or retinal lesions.

Authors:  Ilkay Kilic Muftuoglu; Raouf Gaber; Dirk-Uwe Bartsch; Amit Meshi; Michael Goldbaum; William R Freeman
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-02-28       Impact factor: 3.117

2.  Near-infrared and short-wave autofluorescence in ocular specimens.

Authors:  Yasuharu Oguchi; Tetsuju Sekiryu; Mika Takasumi; Yuko Hashimoto; Minoru Furuta
Journal:  Jpn J Ophthalmol       Date:  2018-08-02       Impact factor: 2.447

3.  Fundus autofluorescence and optical coherence tomography findings in choroidal melanocytic lesions.

Authors:  Miguel A Materin; Raluca Raducu; Carlos Bianciotto; Carol L Shields
Journal:  Middle East Afr J Ophthalmol       Date:  2010-07

Review 4.  Fundus autofluorescence applications in retinal imaging.

Authors:  Andrea Gabai; Daniele Veritti; Paolo Lanzetta
Journal:  Indian J Ophthalmol       Date:  2015-05       Impact factor: 1.848

Review 5.  Using risk factors for detection and prognostication of uveal melanoma.

Authors:  Pukhraj Rishi; Vikram V Koundanya; Carol L Shields
Journal:  Indian J Ophthalmol       Date:  2015-02       Impact factor: 1.848

6.  Clinical, optical coherence tomography, and fundus autofluorescence findings in patients with intraocular tumors.

Authors:  Daniel Samuelsson; Monika Sznage; Karl Engelsberg; Elisabeth Wittström
Journal:  Clin Ophthalmol       Date:  2016-10-07

7.  The advantages of intermediate-tier, inter-optometric referral of low risk pigmented lesions.

Authors:  Angelica Ly; Lisa Nivison-Smith; Michael Hennessy; Michael Kalloniatis
Journal:  Ophthalmic Physiol Opt       Date:  2017-11       Impact factor: 3.117

Review 8.  Fundus Autofluorescence Imaging in Patients with Choroidal Melanoma.

Authors:  Almut Bindewald-Wittich; Frank G Holz; Thomas Ach; Miltiadis Fiorentzis; Nikolaos E Bechrakis; Gregor D Willerding
Journal:  Cancers (Basel)       Date:  2022-04-02       Impact factor: 6.639

9.  Hemorrhagic retinal macrocysts, simulating choroidal melanoma: a case report.

Authors:  Ahmad M Mansour; Mahmoud O Jaroudi
Journal:  Clin Ophthalmol       Date:  2013-05-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.